CoChat
Sign Up
Cited by 9Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women

Open access
Chibwesha, Carla J., Cu-Uvin, Susan·2011·Current HIV/AIDS Reports
DOI 10.1007/s11904-011-0084-6PMC PMC5454481
Open this paper in CoChat — free account

Abstract

Cervical cancer remains the second commonest cancer among women worldwide, and more than 85% of the global burden of this disease occurs in the developing world. HIV-infected women have a higher likelihood of developing persistent high-risk human papillomavirus (HPV) infection, precancer, and invasive cervical cancer than seronegative women. Although highly effective primary and secondary prevention strategies are currently available, they remain inaccessible to the vast majority of women. Because of their simplicity and affordability, see-and-treat cervical cancer screening modalities have the potential to substantially improve women's access to cancer prevention, as well as to create much needed infrastructure for future molecular-based cervical screening and HPV vaccination programs. Additional data addressing the effectiveness of see-and-treat approaches for HIV-infected women are urgently needed. Studies informing best practice guidelines on when to start, when to stop, and how frequently to screen HIV-infected women within the see-and-treat paradigm would be of great value.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11904-011-0084-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tissue specimens were obtained from all treated women, allowing documentation of overtreatment.

    “We were able to document the extent of overtreatment in our study because tissue specimens were obtained from all treated women [24, 31, 32].”

    From HPV Screening in Women Living with HIV (WLHIV) in Karnataka, India: Can it be Integrated into ART Centres? (2025) · cites this paper as [32]

    The Treatment Options section describes LEEP as excising cervical tissue, and the Overtreatment section discusses reported overtreatment rates. Neither section says that specimens were obtained from all treated women in the citing authors’ study or that those specimens enabled its overtreatment assessment. Searches for tissue specimens and histopathology did not establish that claim; page numbers were unavailable in our copy. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. [2]Jemal A Bray F Center MM Global cancer statistics CA Cancer J Clin 2011 61 69 90 21296855
  2. Sahasrabuddhe VV Bhosale RA Kavatkar AN Comparison of visual inspection with acetic acid (VIA) and cervical cytology to detect high grade cervical neoplasia among HIV-infected women in India Int J Cancer 2011 10.1002/ijc.25971 PMC3516675 21387289 · DOI
  3. [4]Gakidou E Nordhagen S Obermeyer Z Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities PLoS Med 2008 5 e132 18563963 PMC2429949
  4. [5]Mandelblatt JS Lawrence WF Gaffikin L Costs and benefits of different strategies to screen for cervical cancer in less-developed countries J Natl Cancer Inst 2002 94 1469 83 12359856
  5. [6]de Sanjose S Quint WG Alemany L Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 2010 11 1048 56 20952254
  6. [7]Castellsague X Natural history and epidemiology of HPV infection and cervical cancer Gynecol Oncol 2008 110 S4 7 18760711
  7. [8]Munoz N Bosch FX de Sanjose S Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 2003 348 518 27 12571259
  8. [9]Smith JS Lindsay L Hoots B Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update Int J Cancer 2007 121 621 32 17405118
  9. [10]Singh DK Anastos K Hoover DR Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women J Infect Dis 2009 199 1851 61 19435429 PMC2814215
  10. [11]Denny L Boa R Williamson AL Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women Obstet Gynecol 2008 111 1380 7 18515522
  11. [12]Kojic EM Cu-Uvin S Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals Curr Opin Oncol 2007 19 464 9 17762572
  12. [13]Sahasrabuddhe VV Mwanahamuntu MH Yèrmund SH Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia Br J Cancer 2007 96 1480 3 17437020 PMC2360194
  13. [14]Moscicki AB Schiffman M Kjaer S Villa LL Chapter 5: Updating the natural history of HPV and anogenital cancer Vaccine 2006 24 Suppl 3 S3/42 51 16950017
  14. [15]Ho GY Bierman R Beardsley L Natural history of cervicovaginal papillomavirus infection in young women N Engl J Med 1998 338 423 8 9459645
  15. [16]Sankaranarayanan R Thara S Esmy PO Basu P Cervical cancer: screening and therapeutic perspectives Med Princ Pract 2008 17 351 64 18685274
  16. [17]Omar T Schwartz S Hanrahan C Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort AIDS 2011 25 87 94 21076276 PMC3166782
  17. [18]Ngoma T Muwonge R Mwaiselage J Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania Int J Gynaecol Obstet 2010 109 100 4 20152973
  18. [19]Mwanahamuntu MH Sahasrabuddhe VV Pfaendler KS Implementation of ‘ see-and-treat’ cervical cancer prevention services linked to HIV care in Zambia AIDS 2009 23 N1 5 19279439 PMC2747794
  19. [20]Blumenthal P Gaffikin L Deganus S Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra, Ghana Am J Obstet Gynecol 2007 196 407.e1 9 17403438
  20. [21]Sankaranarayanan R Rajkumar R Esmy PO Effectiveness, safety and acceptability of ‘see and treat’ with cryotherapy by nurses in a cervical screening study in India Br J Cancer 2007 96 738 43 17311015 PMC2360066
  21. [22]Sangwa-Lugoma G Mahmud S Nasr SH Visual inspection as a cervical cancer screening method in a primary health care setting in Africa Int J Cancer 2006 119 1389 95 16619217
  22. [23]Goldie SJ Gaffikin L Goldhaber-Fiebert JD Cost-effectiveness of cervical-cancer screening in five developing countries N Engl J Med 2005 353 2158 68 16291985
  23. [24]IARC Screening tests Lyon IARC Press 2005
  24. [25]Basu P Sankaranarayanan R Mandal R Evaluation of downstaging in the detection of cervical neoplasia in Kolkata, India Int J Cancer 2002 100 92 6 12115593
  25. [26]Sankaranarayanan R Basu P Wesley RS Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa Int J Cancer 2004 110 907 13 15170675
  26. [27]Arbyn M Sankaranarayanan R Muwonge R Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India Int J Cancer 2008 123 153 60 18404671
  27. [28]Akinwuntan AL Adesina OA Okolo CA Correlation of cervical cytology and visual inspection with acetic acid in HIVpositive women J Obstet Gynaecol 2008 28 638 41 19003664
  28. [30]Sankaranarayanan R Keshkar V Kothari A Effectiveness and safety of loop electrosurgical excision procedure for cervical neoplasia in rural India Int J Gynaecol Obstet 2009 104 95 9 18962583
  29. [31]Luciani S Gonzales M Munoz S Effectiveness of cryotherapy treatment for cervical intraepithelial neoplasia Int J Gynaecol Obstet 2008 101 172 7 18207146
  30. [32]Rema P Suchetha S Thara S Effectiveness and safety of loop electrosurgical excision procedure in a low-resource setting Int J Gynaecol Obstet 2008 103 105 10 18760779
  31. [33]Chirenje ZM Rusakaniko S Akino V Mlingo M A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia J Obstet Gynaecol 2001 21 617 21 12521783
  32. [34]Mitchell MF Tortolero-Luna G Cook E A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix Obstet Gynecol 1998 92 737 44 9794661
  33. [35]Arbyn M Kyrgiou M Simoens C Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis BMJ 2008 337 a1284 18801868 PMC2544379
  34. [36]Crane JM Pregnancy outcome after loop electrosurgical excision procedure: a systematic review Obstet Gynecol 2003 102 1058 62 14672487
  35. [37]Chirenje ZM Rusakaniko S Akino V Effect of HIV disease in treatment outcome of cervical squamous intraepithelial lesions among Zimbabwean Women J Low Genit Tract Dis 2003 7 16 21 17051039
  36. [38]Massad LS Fazzari MJ Anastos K Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV J Low Genit Tract Dis 2007 11 90 7 17415113
  37. [39]Lima MI Tafuri A Araujo AC Cervical intraepithelial neoplasia recurrence after conization in HIV-positive and HIVnegative women Int J Gynaecol Obstet 2009 104 100 4 19062013
  38. [40]Brockmeyer AD Wright JD Gao F Powell MA Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure Am J Obstet Gynecol 2005 192 1379 81 15902114
  39. [41]Wright TC Jr Koulos J Schnoll F Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision Gynecol Oncol 1994 55 253 8 7959293
  40. [42]Leguevaque P Motton S Decharme A Predictors of recurrence in high-grade cervical lesions and a plan of management Eur J Surg Oncol 2010 36 1073 9 20870375
  41. Chamot E Kristensen S Stringer JS Mwanahamuntu MH Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review BMC women’s health 2010 10 11 20359354 PMC2858093
  42. [44]Kietpeerakool C Suprasert P Srisomboon J Outcome of loop electrosurgical excision for HIV-positive women in a low-resource outpatient setting Int J Gynaecol Obstet 2009 105 10 3 19084838
  43. [45]Pfaendler KS Mwanahamuntu MH Sahasrabuddhe VV Management of cryotherapy-ineligible women in a “screen-and-treat” cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field Gynecol Oncol 2008 110 402 7 18556050 PMC2745977
  44. [46]van Bogaert LJ Age at diagnosis of preinvasive and invasive cervical neoplasia in South Africa: HIV-positive versus HIVnegative women Int J Gynaecol Obstet 2011 21 363 6 21270617
  45. [48]WHO Comprehensive cervical cancer control: A guide to essential practice WHO 2006 25642554
  46. [49]Kim JJ Leung GM Woo PP Goldie SJ Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong J Public Health 2004 26 130 7 15284314
  47. [50]Goldie SJ Kuhn L Denny L Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness JAMA 2001 285 3107 15 11427139
  48. [51]Cremer M Conlisk E Maza M Adequacy of visual inspection with acetic acid in women of advancing age Int J Gynaecol Obstet 2011 113 1 68 71 21272884
  49. [52]Adam Y van Gelderen CJ Newell K ‘Look and Lletz’-a Chris Hani Baragwanath Hospital experience S Afr Med J 2008 98 119 22 18350207
  50. [53]Denny L Kuhn L De Souza M Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial JAMA 2005 294 2173 81 16264158
  51. [54]Quinn TC Wawer MJ Sewankambo N Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group N Engl J Med 2000 342 921 9 10738050
  52. [55]Wright TC Jr Subbarao S Ellerbrock TV Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration Am J Obstet Gynecol 2001 184 279 85 11228474
  53. [56]Chung M McKenzie K Richardson B Cervical HIV-1 RNA shedding after cryotherapy among HIV+ women with cervical intraepithelial neoplasia 2/3 18th Conference on Retroviruses and Opportunistic Infections Boston, USA 2011
  54. [57]Tsu VD Levin CE Making the case for cervical cancer prevention: what about equity? Reprod Health Matters 2008 16 104 12 19027628
  55. [58]Denny L Quinn M Sankaranarayanan R Chapter 8: Screening for cervical cancer in developing countries Vaccine 2006 24 Suppl 3 S3/71 7 16950020
  56. [59]Denny L Kuhn L Hu CC Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial J Natl Cancer Inst 2010 102 1557 67 20884893
  57. Kuhn L Wang C Tsai WY Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women AIDS 2010 24 2553 61 20706107
  58. Sankaranarayanan R Nene BM Shastri SS HPV screening for cervical cancer in rural India N Engl J Med 2009 360 1385 94 19339719
  59. Lu B Kumar A Castellsague X Giuliano AR Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis BMC infectious diseases 2011 11 13 21226933 PMC3034689
  60. [63]FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions New Eng J Med 2007 356 1915 27 17494925
  61. [64]Harper DM Franco EL Wheeler CM Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial Lancet 2006 367 1247 55 16631880
  62. [65]Harper DM Franco EL Wheeler C Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 2004 364 1757 65 15541448
  63. Levin MJ Moscicki AB Song LY Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old J Acquir Immue Defic Syndr 2010 55 197 204 PMC3033215 20574412

Cited by

Sorted by citations

Authors
Chibwesha, C. J., & Cu-Uvin, S.
Affiliations
Centre for Infectious Disease Research in Zambia (ZM)
Corresponding author
Chibwesha, Carla J.
ORCID
Chibwesha, Carla J.
Venue
Current HIV/AIDS Reports
Publisher
Springer Science and Business Media LLC
Published
2011-06-25
Volume
8
Issue
3
Pages
192-199
ISSN
  • 1548-3568 (ISSN-L)
  • 1548-3576
DOI
10.1007/s11904-011-0084-6
PMC
PMC5454481
OpenAlex
W2016488261
Cited by
9
References
1
Citations by year
2026: 1 · 2022: 1 · 2020: 1 · 2019: 1 · 2017: 2 · 2016: 1 · 2014: 1 · 2012: 1
FWCI
0.48
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Current HIV/AIDS Reports (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Vanderbilt University
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (K24AI066884, P30AI042853)
  • Fogarty International Center (R24TW007988)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
cervical cancer, women living with HIV, cervical cancer screening, human papillomavirus, high-risk HPV infection, cervical precancerous lesions, cervical cancer prevention, screening frequency
MeSH terms
Uterine Cervical Neoplasms, Female, HIV, Humans, Predictive Value of Tests, Sensitivity and Specificity, HIV Infections, Papillomavirus Infections, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review